Lederle/Wyeth-Ayerst Verelan comarketing
Will put combined sales force of 1,500 reps behind once-a-day verapamil, not 2,500 as recently reported ("The Pink Sheet" July 16, "In Brief").
You may also be interested in...
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.
CDRH director Jeff Shuren says the US agency’s device center has been tallying up lessons learned from the COVID-19 pandemic.